This content is in French.
Treatment of prostate cancer with GnRH agonists: what is the real impact on quality of life?
17 novembre 2025
By Lila Rouland | Published on November 17, 2025 | 3 min readProstate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL). Fatigue, mood
By Lila Rouland | Published on November 17, 2025 | 3 min read
Prostate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL). Fatigue, mood disturbances, hot flashes, and decreased libido are among the most frequently reported complaints. The PRISME study, a French multicenter observational project, aimed to precisely measure the evolution of QoL in patients starting GnRH agonist therapy under real-world clinical conditions.
Prostate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL). Fatigue, mood disturbances, hot flashes, and decreased libido are among the most frequently reported complaints. The PRISME study, a French multicenter observational project, aimed to precisely measure the evolution of QoL in patients starting GnRH agonist therapy under real-world clinical conditions.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study. Duchesne G, Cornu JN, Allory Y, et al. Progres en Urologie. 2022;32(5):347-356.
View the source
